PLoS ONE (Jan 2018)

Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain.

  • M Jesus Purriños-Hermida,
  • María Isolina Santiago-Pérez,
  • Mercedes Treviño,
  • Rafaela Dopazo,
  • Angelina Cañizares,
  • Isolina Bonacho,
  • Matilde Trigo,
  • M Eva Fernández,
  • Ana Cid,
  • David Gómez,
  • Patricia Ordóñez,
  • Amparo Coira,
  • M J Armada,
  • Magdalena Porto,
  • Sonia Perez,
  • Alberto Malvar-Pintos,
  • HPV Vaccine Impact Surveillance Working Group of Galicia

DOI
https://doi.org/10.1371/journal.pone.0201653
Journal volume & issue
Vol. 13, no. 8
p. e0201653

Abstract

Read online

Bivalent human papillomavirus (HPV) vaccine was incorporated into the childhood vaccination calendar in Galicia, Spain in 2008. The objectives of this study were to estimate direct, indirect and total effectiveness of HPV vaccine and to identify sexual habits changes in the post-vaccination period in Galicia, Spain.Endocervical scrapings of 745 women attending 7 Health Areas of the Galician Public Health Service were collected in the post-vaccination period, from 2014-2017. Two groups were studied: women born between 1989 and 1993 (n = 397) and women born in 1994 or later (n = 348). Twelve high-risk human papillomavirus (HR-HPV) genotypes were detected by Cobas® 4800 HPV test (Roche Diagnostics, Mannheim, Germany). The Linear Array® HPV Genotyping Test (Roche Diagnostics) was used for HR-HPV genotype detection other than HPV 16/18. Information about sexual habits was collected by a self-filled questionnaire. Post-vaccination data were compared to previously published pre-vaccination data obtained between 2008 and 2010 in Galicia from women of the same age (18-26 years old, n = 523). The Stata 14.2 software was employed for statistical analyses.Data from 392 unvaccinated and 353 vaccinated women were compared. For unvaccinated and vaccinated women, HPV 16/18 prevalence was 9.2% and 0.8%, respectively, and HPV 31/33/45 prevalence was 8.4% and 1.1%, respectively. Direct, indirect and total effectiveness of the HPV vaccine were (%, 95% CI): 94 (72-99), 30 (-11-56) and 95 (79-99), respectively, for HPV 16/18 and 83 (46-94), -10 (-88-33) and 84 (54-94), respectively, for HPV 31/33/45. The number of women with first intercourse before 17 years old and 3 or more sexual partners along life was higher in the post-vaccination period (p < 0.05). A positive impact of bivalent HPV vaccine was observed, both on direct and cross protection. Sexual habits could have changed in the post-vaccination period.